Disease Progression Study for the Treatment of RRMS

- Relapsing Remitting Multiple Sclerosis
- Terminated

Study Title: Randomized Study Designed to Look at Disease Progression Using 2 Currently FDA Approved Drugs for the Treatment of RRMS

Teva Identifier: 9013

ClinicalTrials.gov Identifier: NCT00202995

Study Status: Terminated

Trial Condition(s): Relapsing Remitting Multiple Sclerosis

Interventions: Drug: Glatiramer Acetate | Drug: Betaseron | Drug: Rebif

Study Description

Please refer to ClinicalTrials.gov for a description of the trial

Participation criteria and map of study locations

Key Participation Requirements

Gender: Female, Male

Age group: Adult

Age Range: 18 Years to 50 Years

Trial Duration: 07/01/2004 - 10/01/2007

Phase: Phase 4

Study Type

Interventional